Natera (NTRA) is back on investor radar after Stanley Druckenmiller's family office made the stock its largest holding. This coincides with strong revenue growth, higher test volumes, and improving free cash flow.

Natera’s recent news on clinical collaborations and higher test volumes sits alongside strong momentum in the stock. The 30 day share price return of 26.73% and 1 year total shareholder return of 104.36% point to building enthusiasm, while the latest close at $332.03 keeps attention on how expectations align with the company’s execution and risk profile.

If Natera’s surge has you looking across healthcare, now could be a good moment to scan other opportunities in this space using the 41 healthcare AI stocks

Bulls see Natera’s recent surge and cash flow progress as confirmation of a leading genetic testing platform. Bears see frothy expectations. Which case does the current valuation support as you weigh the recent move?

Most Popular Narrative: 18% Overvalued

Natera’s most followed valuation narrative puts fair value at $282.14, which sits below the last close at $332.03, so the story leans toward a rich pricing profile built on ambitious long term assumptions.

Increasing adoption and acceptance of advanced molecular diagnostics is driving sustained volume and revenue growth across Natera's diversified portfolio, with significant headroom remaining for further penetration particularly in oncology (Signatera) and organ health (Prospera); this will likely boost top-line revenue.

Want to see what underpins that premium tag on Natera? The narrative leans on steep revenue ramps, margin expansion, and a future earnings profile that implies a very rich earnings multiple.

Result: Fair Value of $282.14 (OVERVALUED)

However, investors in Natera still need to watch for setbacks in clinical trials or reimbursement decisions, as well as continued high R&D and SG&A spending that could pressure profitability.

Another View On Natera’s Valuation

While the most popular narrative pegs Natera at about 18% above fair value using forward earnings assumptions, the SWS DCF model points in the opposite direction. On this view, the stock at $332.03 trades roughly 45% below an estimated value of $604.78. Which story fits your own expectations for the business?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Natera for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Natera presenting a mix of optimism and caution, it makes sense to move fast and check the underlying data yourself. To weigh the upside against the concerns in a clear way, review the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Natera?

Do not stop with Natera. Use this momentum to widen your watchlist and spot other stocks that fit your risk, income, or quality preferences.

• Target potential mispricing by scanning 48 high quality undervalued stocks that combine stronger fundamentals with valuations that may not fully reflect their financial profile.
• Strengthen your income stream by reviewing 12 dividend fortresses that focus on higher yielding companies with payouts that may appeal to dividend focused investors.
• Dial back portfolio risk by filtering for 75 resilient stocks with low risk scores that score well on financial robustness and volatility measures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.